Impact of CSF3R Mutation on Treatment Response and Survival of Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.03.002
- Author:
Ruo-Qi LI
1
,
2
;
Xiao-Ling WEN
1
,
2
;
Xia-Lin ZHANG
3
;
Chun-Xia DONG
1
,
2
;
Mei-Fang WANG
1
,
2
;
Xia-Xia LIU
1
,
2
;
Yan-Jun HUANG
1
,
2
;
Yan-Hong TAN
1
,
2
;
Jian-Mei CHANG
1
,
2
;
Rui-Juan ZHANG
4
Author Information
1. Department of Hematology, The Second Hospital of Shanxi Medical University
2. Taiyuan 030001, Shanxi Province, China.
3. Department of Hematology, The Third Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
4. Department of Hematology, The Third Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China .E-mail: 13593169668@163.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
prognosis;
treatment response
- MeSH:
Middle Aged;
Humans;
Male;
Female;
Aged;
Leukemia, Myelomonocytic, Acute;
Retrospective Studies;
Leukemia, Myeloid, Acute/diagnosis*;
Prognosis;
Mutation;
Receptors, Colony-Stimulating Factor/genetics*
- From:
Journal of Experimental Hematology
2023;31(3):628-632
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of CSF3R mutation in acute myeloid leukemia (AML) and analyze its clinical characteristics and prognosis.
METHODS:A retrospective study was conducted in 212 patients with AML who were newly diagnosed in the Second Hospital of Shanxi Medical University from January 1th 2018 to June 30th 2021, including 22 patients with CSF3R mutations as mutation group and 190 patients with CSF3R wild type ［66 cases of them were screened by propensity score matching (PSM), as control group］. The early efficacy and survival between the two groups were compared.
RESULTS:The median age of patients in the mutation group was 50(17-73) years old, and the ratio of male to female was 1.2:1 The main types were AML with maturation (11 cases) and acute myelomonocytic leukemia (9 cases). Prognostic stratification was carried out according to the risk stratification system of the European leukemia network in 2017, with 16 cases (72.73%) in the middle and high-risk group. At the initial diagnosis, the median count of white blood cell (WBC) was 44.75(1.30-368.71)×109/L, among which 15 cases (68.18%) were >10×109/L, and the median count of platelet (PLT) was 24(4-55)×109/L. CSF3R T618I (68.18%) was a common mutation site, which had concomitant gene mutations, in which CEBPA mutation was the most common (10 cases, 45.45%), but only existed in CSF3R T618I mutation. The CR/CRi rate was 68.18% and 71.21% in the mutant group and the control group (P >0.05), the median over all survival time was 15 months and 9 months (P >0.05), and the median disease-free survival time was 8 months and 4 months (P >0.05), respectively.
CONCLUSION:Most AML patients with CSF3R mutation are middle-aged patients, the main types are AML with maturation and acute myelomonocytic leukemia, and most of them have middle and high-risk prognosis. CSF3R mutation may not be an independent prognostic marker for newly diagnosed AML patients.
